Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week randomized double-blind placebo-controlled trial of CAD106 in mild Alzheimer's disease
2007-003973-16Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2007
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing CAD106 150 µg with Placebo (2 arms). Primary endpoint: Safety and tolerability of CAD106. Started Sep 2007; status: completed.
02
Drugs
amilomotide
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2007-003973-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003973-16.